The assistant professor of neurology at the University of North Carolina at Chapel Hill discussed the importance of recognizing disability as part of diversity in neurology, emphasizing the need for inclusive communication and accessibility for disabled patients. [WATCH TIME: 10 minutes]
The associate professor of neurology at Albert Einstein College of Medicine talked about a review on neonatal seizures recently published in the New England Journal of Medicine. [WATCH TIME: 5 minutes]
The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided commentary on the possibility of preventing NMOSD, and the need to improve access to approved therapies and AQP4 testing. [WATCH TIME: 3 minutes]
Bruce Hughes, MD, comments on the current use and access to biomarkers in MS management, as well as sharing how NfL is being used in clinical practice presently.
An expert neurologist discusses pNfL being utilized outside of clinical trials and implemented into clinical practice for the treatment of MS.
Bruce Hughes, MD, reviews clinical trials of use of NfL in MS, highlighting data on the Bruton’s tyrosine kinase inhibitor, evobrutinib.
Bruce Hughes, MD, provides an overview of the use of neurofilament light chain (NfL) as a biomarker in multiple sclerosis (MS), highlighting the accuracy and reliability of plasma/serum NfL (pNfL) and cerebrospinal fluid (CSF) NfL measurements.
The associate professor at the University of Colorado talked about a study involving pediatric patients with multiple sclerosis and related disorders, and the risk of COVID-19 infection among those on B-cell-depleting therapy. [WATCH TIME: 5 minutes]
Anne Marie Morse, DO, FAASM, discusses the efficacy and safety profile of pitolisant for the treatment of narcolepsy.
Thomas E. Scammell, MD, provides an overview of the mechanism of action of pitolisant for the treatment of narcolepsy.
The neurology PGY-3 at Mayo Clinic in Arizona talked about findings from a retrospective cohort study that examined blood pressure in patients who were prescribed a migraine medication. [WATCH TIME: 6 minutes]
Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, discuss a patient case with relapsing/remitting multiple sclerosis progression and share considerations for switching treatment.
Expert neurologists review treatment options for a young female with relapsing remitting multiple sclerosis (RRMS).
The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided insight on the necessary research needed to understand why certain races experience more significant multiple sclerosis disease progress. [WATCH TIME: 4 minutes]
At the 2023 AAN Annual Meeting, the neuromuscular disease specialist and professor of neurology at the University of Kansas Medical Center talked about the phase 3 study investigating ataluren for Duchenne muscular dystrophy. [WATCH TIME: 5 minutes]
The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed findings from the phase 3 CHAMPION-NMOSD trial of ravulizumab in patients with neuromyelitis optica spectrum disorder. [WATCH TIME: 5 minutes]
At the 2023 AAN Annual Meeting, the professor of neurology at the Geisel School of Medicine at Dartmouth talked about the effectiveness of a remote electrical neuromodulation device that offers potential relief for both episodic and chronic migraine. [WATCH TIME: 3 minutes]
The panel shares final advice for the multiple sclerosis community.
Craig Mainor shares advice for people living with multiple sclerosis and their families.
The senior academic at the University of Sydney discussed the reasons for using BC-LCLA and the modified MS Functional Composite in the phase 2 VISIONARY-MS trial. [WATCH TIME: 3 minutes]
At the 2023 AAN Annual Meeting, the chief medical officer at Athira Pharma spoke about findings from a phase 2 trial in which various biomarkers related to neurodegeneration showed significant improvements. [WATCH TIME: 4 minutes]
Neurology News Network for the week ending May 13, 2023. [WATCH TIME: 4 minutes]
The senior academic at the University of Sydney provided perspective on the promising findings of the phase 2 VISIONARY-MS study of CNM-Au8 in relapsing multiple sclerosis. [WATCH TIME: 6 minutes]
The professor of neurology at NYU Grossman School of Medicine and chief medical officer of the Epilepsy Foundation spoke about her talk on new treatments for drug resistant epilepsy given at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]
The medical director of SleepMed in South Carolina provided perspective on the importance of understanding the link between sleep disorders, poor sleep, and heart health. [2 minutes]
The CEO and cofounder of Amprion spoke about additional diagnostic uses of the αSyn seed amplification assay and its validation in the Parkinson's Progression Markers Initiative study at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]
The chief scientific officer at Alzheon provided insight on the preliminary imaging findings of patients enrolled in the phase 3 APOLLOE4 study assessing ALZ-801 as a potential treatment for Alzheimer disease. [WATCH TIME: 3 minutes]
The chief executive officer and president of Study Metrics Research provided commentary on a large-scale analysis further demonstrating efficacy and safety of zavegepant, regardless of aura status. [WATCH TIME: 3 minutes]
Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, consider reasons to use generic disease-modifying therapies (DMTs) as a first-line therapy in the treatment of relapsing remitting multiple sclerosis (RRMS).
Experts in neurology highlight factors that lead them to choose certain therapies to treat relapsing remitting multiple sclerosis (RRMS), such as high efficacy in clinical trials.
